569253-U

Discovery^® HS C18 (3 µm) HPLC Columns

L × I.D. 5 cm × 2.1 mm, HPLC Column

• Sinonimo/i: Discovery RP18 HPLC Column
• Codice UNSPSC: 41115700
• eCl@ss: 32110501
• NACRES: SB.52

Proprietà

• product name: Colonna HPLC Discovery^® HS C18, 3 μm particle size, L × I.D. 5 cm × 2.1 mm
• Materiali: stainless steel column
• agenzia: suitable for USP L1
• Nome Commerciale: Discovery^®
• Caratteristiche: endcapped
• Produttore/marchio commerciale: Discovery^®
• Confezionamento: 1 ea of
• Grado di funzionalizzazione: 20% Carbon loading
• Parametri: ≤70 °C temp. range; 400 bar pressure (5801 psi)
• tecniche: HPLC: suitable; LC/MS: suitable
• Lungh. × D.I.: 5 cm × 2.1 mm
• Area superficiale: 300 m²/g
• Copertura della superficie: 3.2 μmol/m²
• Impurezze: <10 ppm metals
• Matrice: silica gel, high purity, spherical particle platform; fully porous particle
• Gruppo funzionale matrice: C18 (octadecyl) phase
• Dimensione particelle: 3 μm
• Dimensione pori: 120 Å
• operating pH range: 2-8
• applicazioni: food and beverages
• Tecnica di separazione: reversed phase

Descrizione

Descrizione generale

Discovery^® HS C18 HPLC column (L × I.D. 5 cm × 2.1 mm) is commonly found to be stable under acidic and basic conditions.

Applicazioni

• Stereoselective separation of omeprazole and 5-hydroxy-omeprazole using dried plasma spots and a heart-cutting 2D-LC approach for accurate CYP2C19 phenotyping: This research utilizes the Discovery^® HS C18 HPLC column for its superior selectivity and sensitivity in pharmacogenetic studies, providing vital data for personalized medicine approaches in drug metabolism (Abouir et al., 2024).


• A stability indicating RP-HPLC method for determination of the COVID-19 drug molnupiravir applied using nanoformulations in permeability studies: This study highlights the effectiveness of the Discovery^® HS C18 column in the rapid and accurate analysis of molnupiravir, emphasizing its role in supporting fast-paced pharmaceutical research and development (Reçber et al., 2022).


• Sensitive Analysis of Idarubicin in Human Urine and Plasma by Liquid Chromatography with Fluorescence Detection: This application underlines the Discovery^® HS C18 column′s high sensitivity and robustness in clinical diagnostics, crucial for monitoring therapeutic drugs and their metabolites in complex biological matrices (Maliszewska et al., 2020).

Caratteristiche e vantaggi

• Stabile, a bassa perdita per applicazioni LC-MS
• Scalabile dalla colonna analitica alla preparatoria
• Molto stabile per garantire una eccellente riproducibilità da un ciclo all′altro e da un lotto all′altro
• Maggiore idrofobia per una migliore risoluzione degli analiti difficili

   

Prodotti consigliati

Discover LiChropur reagents ideal for HPLC or LC-MS analysis

Note legali

Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany